Once the cancer has been diagnosed, the patient routinely has to go for conventional
chemotherapy regimen. However, these chemo sessions are common to all patients with
that specific cancer type. This uniform approach to the treatment is one of the most
important reasons of treatment fatalities, deaths, and cancer recurrence. ‘One size fits all’
proves harmful in this case.
Cancer has unique properties and differs in every patient and hence every patient responds
in a very different manner to the same chemotherapy. Thus, a few patients undergo
remission whereas few have cancer progression even after receiving cancer treatment. It is
harmful because this cancer progression or failure of treatment becomes evident after
many days of receiving the chemotherapy and after suffering all the side effects of the
Time & Money
Trial & error approach proves very hazardous in this case the time is very precious for
successful cancer management and this precious time is lost with the conventional method.
At the same time, precious financial resources are wasted in drugs with no benefits and
give harsh side effects. Hence it is very beneficial for the patient and the treating physician,
if it is already known which drugs will give maximum benefit in that individual patient’s
Correkt-chemo directly tests the effect of chemotherapy / anti- cancer drugs on the
patient’s tumor cells. It helps to customize the treatment plan according to sensitivity and
resistance pattern of the patient’s tumor cells. When armed with this information, patient’s
physician can ensure that they receive the most effective chemotherapy from all available
options. This personalization of the chemotherapy by directly studying effect of
chemotherapy drugs on cells taken from fresh biopsy sample of the tumor – is the Correkt-
chemo test. In this test, fresh tumor cells obtained by biopsy / surgery are treated with
different chemotherapy drugs. The effect of drug is measured directly by its ability to kill
the tumor cells. Consequent upon this information, the drugs are listed in their order of
comparative efficacy to kill the tumor cells.
Who should undergo this test?
- Every cancer patient with or without metastasis, before starting cancer treatment.
- Every patient who is under treatment for cancer.
- Every patient in whom the cancer is not responding satisfactorily to therapy.